Joven Dungo, MD
Cardiovascular Disease · Jersey City, NJNPI 1386726230
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.8%), other and education — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Abbott at 55.1% of the total. Reporting peaked in 2021 at $56,216 and has fallen 84.2% since, to $8,858 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,755 payments — averaging $59.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$57K
- AstraZeneca$6K
- Boehringer Ingelheim$5K
- GSK$3K
- Amgen$3K
- Johnson & Johnson$3K
- plus $25K from 52 others
What the payments were for
- Food & beverage$52,60051%
- Education$1490%
- Other$50,80049%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$2,463
- Reltone 200 Mg$1,719
- GLYCATE$1,719
- Reltone 400 Mg$1,719
- XARELTO$1,407
- BREZTRI$1,331
- TRELEGY ELLIPTA$1,205
- SAPIEN 3 Ultra RESILIA$1,066
- Confirm Rx$994
- AIRSUPRA$963
- AREXVY$940
- Ozempic$851
- INGREZZA$832
- KRYSTEXXA$762
- LifeVest$601
- FARXIGA$597
- AVEIR$563
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$431
- NURTEC ODT$395
- UBRELVY$367
How this compares
$103,549 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 16 | $742,232 |
| KorlymMifepristone | 19 | $586,646 |
| JardianceEmpagliflozin | 172 | $246,277 |
| OzempicSemaglutide | 88 | $168,998 |
| XareltoRivaroxaban | 135 | $145,480 |
| RybelsusSemaglutide | 54 | $134,589 |
| VascepaIcosapent Ethyl | 136 | $111,783 |
| ReltoneUrsodiol | 53 | $105,332 |
| EliquisApixaban | 75 | $102,202 |
| TrulicityDulaglutide | 38 | $100,967 |
| SynjardyEmpagliflozin/Metformin Hcl | 74 | $98,386 |
| Ursodiol | 30 | $93,175 |
| LinzessLinaclotide | 69 | $74,783 |
| Praluent PenAlirocumab | 62 | $67,852 |
| JubliaEfinaconazole | 16 | $67,112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa, Prolia | $3,406 | $761,70428 claims |
| Corcept TherapeuticsKorlym | $1,627 | $586,64619 claims |
| Boehringer IngelheimJardiance, Synjardy, Tradjenta | $4,841 | $358,758267 claims |
| Novo NordiskOzempic, Rybelsus | $2,350 | $303,588142 claims |
| Johnson & JohnsonXarelto | $3,205 | $145,480135 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra | $6,191 | $109,82392 claims |
| Intra-sana LaboratoriesReltone | $1,943 | $105,33253 claims |
| PfizerEliquis | $321 | $102,20275 claims |
| Lilly USA, LLCTrulicity | $647 | $100,96738 claims |
| AbbVieLinzess | $2,551 | $74,78369 claims |
| MerckJanuvia, Verquvo, Janumet | $1,264 | $74,19953 claims |
| GSKTrelegy Ellipta | $3,449 | $57,38358 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Jersey City
- Muhammad HaqJersey City$31K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.